BT Group Transforms its Business Approach with a Cloud Core Network from Juniper Networks to Enable New Services at Exceptional Scale and Quality Globally
19.7.2023 11:00:00 EEST | Business Wire | Press release
Juniper Networks (NYSE:JNPR), a leader in secure, AI-driven networks, today announced it is supporting BT Group’s ongoing transformation journey towards a highly scalable, automated and robust cloud core infrastructure for business and consumer customers. BT Network Cloud supports diverse network applications across broadband, fixed, mobile and other mission-critical services on a single platform, using Juniper Networks’ high-performance cloud-native solutions and professional services.
With this strategic deployment, BT Network Cloud has now scaled to accommodate multiple key network-centric applications, such as mobile voice and data, broadband authentication and IP voice calls for tens of millions of customers without extra overhead costs. An innovative global technology footprint from Juniper, including infrastructure consolidation and virtualization, along with improved hardware density and power efficiency, reduces space and power requirements in support of a more sustainable infrastructure.
BT Simplifies and Improves Service Quality with Agile Network Cloud
BT Network Cloud enables applications that underpin BT Group's U.K. consumer and business network services. Juniper’s high-performance, high-availability fabric for BT Network Cloud provides extreme robustness and high performance for BT Group’s core applications across a widely distributed user base deployed at multiple locations across the U.K. Moving from dedicated compute platforms for each application to a shared infrastructure conserves and optimizes resources leading to better resource utilization and significantly lower environmental impact.
The provider’s network cloud optimizes service quality and streamlines operational deployment and management of core applications, which enables innovation and agility in delivering new services to market such as enhanced 5G services.
5G Roll Out and Scale to Meet Digital Demand
The introduction of 5G created a unique opportunity for BT Group to transform its core network to ensure it was well-positioned to offer a dynamic range of new services to customers at unprecedented scale. BT Group chose to build a network cloud to provide a common shared platform for core applications, which operate its broadband, fixed and mobile services. BT Group has migrated tens of millions of mobile subscribers and successfully deployed all its mobile application infrastructure on its network cloud.
The goal of the multiyear journey at BT Group was to deploy a state-of-the-art container-based fixed, broadband and mobile core that will boost business agility, operational efficiency, sustainability and meet security compliance.
News Highlights:
-BT uses Juniper for open, software-defined networking (SDN), switching and firewall solutions for its network cloud. The service provider uses Juniper’s SDN platform to automate the creation and management of its OpenStack-based telco cloud. The platform provides hybrid SDN orchestration and centralized control of virtual switching, routing and security. BT is running cloud-native containerized applications and optimizing costs using OpenStack.
-Juniper QFX Series Switches provide the high-performance, high-availability fabric needed to support the BT Network Cloud which has rapidly become the largest container-based cloud infrastructure in the world, and is still growing.
-BT’s cloud-native platform is deployed at multiple locations across the U.K. to form a distributed architecture designed to scale seamlessly alongside demand and to provide services closer to the end user than with traditional, more centralized deployments.
-Juniper collaborated with BT to deliver high-performance, high-availability fabric for BT Network Cloud. BT’s data centers contain over 1,000 Juniper QFX Series Switches and 2,000 Juniper vRouters. The switches connect all mission-critical application servers to the core network. The SDN platform is deployed on the servers to provide virtualized routing capability to connect workloads across BT’s network securely.
-Juniper vSRX Virtual Firewalls protect and secure the data center traffic. vSRX provides a network address translation capability which was not possible for one of BT’s application providers to deliver in software.
-BT Group selected Juniper for its engineering excellence and ability to provide an end-to-end network solution including hardware, software and tools that can integrate reliably with the complete cloud stack.
-By leveraging Juniper’s professional services, BT has successfully completed the project on time and ensured that the challenging service level, availability and performance targets of BT’s applications are met.
Supporting Quotes:
“Telecoms services have become central to business and consumer lives and as the U.K.’s national network provider, BT Group has a particular responsibility to lead from the front to deliver the cloud-native, sustainable digital services of the future. Our work with partners such as Juniper is helping to ensure that our critical infrastructure, network and services are agile, secure and resilient for the long term. Our millions of customers can remain confident in the experience-led integrity of the everyday and exceptional digital services on which they rely.”
- Howard Watson, Chief Security and Networks Officer, BT Group
“We are delighted that Juniper’s cloud-native networking solutions and comprehensive professional services were selected as the cornerstone of the BT Network Cloud. BT can respond to the demands of the next chapter of digital transformation at scale whilst leveraging the power of the network to enable new digital services for BT’s customers, fully supported by a cloud-native architecture enabling security, automation, scale and agility.”
- Raj Yavatkar, Chief Technology Officer, Juniper Networks
Additional Resources
BT: Success Story
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719046766/en/
Contact information
Media Relations:
Pelin Murphy
Juniper Networks
pelin@juniper.net
+44 (0) 1372 385 686
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
